1030 related articles for article (PubMed ID: 17694093)
81. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.
Vaquero A; Sternglanz R; Reinberg D
Oncogene; 2007 Aug; 26(37):5505-20. PubMed ID: 17694090
[TBL] [Abstract][Full Text] [Related]
82. Design of novel histone deacetylase inhibitors.
Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
[TBL] [Abstract][Full Text] [Related]
83. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
84. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
Yang XJ; Seto E
Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
[TBL] [Abstract][Full Text] [Related]
85. Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer.
Riester D; Hildmann C; Schwienhorst A; Meyer-Almes FJ
Anal Biochem; 2007 Mar; 362(1):136-41. PubMed ID: 17250798
[TBL] [Abstract][Full Text] [Related]
86. Histone deacetylases and cancer.
Glozak MA; Seto E
Oncogene; 2007 Aug; 26(37):5420-32. PubMed ID: 17694083
[TBL] [Abstract][Full Text] [Related]
87. Class IIa histone deacetylases: regulating the regulators.
Martin M; Kettmann R; Dequiedt F
Oncogene; 2007 Aug; 26(37):5450-67. PubMed ID: 17694086
[TBL] [Abstract][Full Text] [Related]
88. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
89. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
Ungerstedt JS; Sowa Y; Xu WS; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):673-8. PubMed ID: 15637150
[TBL] [Abstract][Full Text] [Related]
90. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
91. HDACi: cellular effects, opportunities for restorative dentistry.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Dent Res; 2011 Dec; 90(12):1377-88. PubMed ID: 21536971
[TBL] [Abstract][Full Text] [Related]
92. Histone deacetylase inhibitors in programmed cell death and cancer therapy.
Marks PA; Jiang X
Cell Cycle; 2005 Apr; 4(4):549-51. PubMed ID: 15738652
[TBL] [Abstract][Full Text] [Related]
93. RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Zhu Y; Das K; Wu J; Lee MH; Tan P
Oncogene; 2014 Mar; 33(12):1527-37. PubMed ID: 23584480
[TBL] [Abstract][Full Text] [Related]
94. The structure and function of histone deacetylases: the target for anti-cancer therapy.
Zhang Y; Fang H; Jiao J; Xu W
Curr Med Chem; 2008; 15(27):2840-9. PubMed ID: 18991639
[TBL] [Abstract][Full Text] [Related]
95. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
96. An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme.
Moreth K; Riester D; Hildmann C; Hempel R; Wegener D; Schober A; Schwienhorst A
Biochem J; 2007 Feb; 401(3):659-65. PubMed ID: 17037985
[TBL] [Abstract][Full Text] [Related]
97. Eosin Y as an internal standard for a plate reader-based quantitation of a histone deacetylase substrate.
Heltweg B; Jung M
Arch Pharm (Weinheim); 2002 Jun; 335(6):296-300. PubMed ID: 12210773
[TBL] [Abstract][Full Text] [Related]
98. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
99. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
100. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
